<DOC>
	<DOCNO>NCT00196586</DOCNO>
	<brief_summary>The purpose pilot study evaluate efficacy safety addition IL-2 pegylated interferon alpha 2a ribavirin HIV-HCV coinfected patient non-responders three month standard therapy pegylated interferon alpha 2a ribavirin . IL-2 may enhance number function CD4 T lymphocytes specific anti-HCV immune response could participate control HCV replication</brief_summary>
	<brief_title>Efficacy Safety Addition IL-2 Pegylated Interferon Alpha 2a Ribavirin HIV/HCV Coinfected Patients</brief_title>
	<detailed_description>This pilot study evaluate efficacy safety addition IL-2 pegylated interferon alpha 2a ribavirin HIV-HCV coinfected patient non-responders three month standard therapy pegylated interferon alpha 2a ribavirin Eligible patient CD4 cell count high 300/mm³ pretreated antiretroviral therapy high 400/mm³ naive antiretroviral therapy , Metavir score histological fibrosis score F1 , F2 F3 . Recombinant IL-2 give subcutaneously dose 3 MUI twice daily 5 day every 8 week 5 cycle week 14 week 46 . This national multicenter study enroll around 75 patient order give IL-2 20 non-responders . The primary endpoint sustain virologic response , define undetectable serum HCV-RNA week 72 , six month end therapy</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>HIV1 infection HCV infection Naive ribavirin CD4 high 300 pretreated antiretroviral therapy high 400 naive antiretroviral therapy Signed informed consent Cirrhosis ( histological fibrosis score F4 Metavir score ) Other liver disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Pegylated interferon alpha 2</keyword>
	<keyword>ribavirin</keyword>
</DOC>